Loading…
Rapport Therapeutics Inc Is A Clinical-Stage Biotechnology Company Dedicated To The Discovery And Development Of Small-Molecule Precision Medicines For Patients With Neurological Or Psychiatric Disorders. The Company'S Portfolio Of Programs From Its Rap Technology Platform Includes Rap-219, An Investigational Small Molecule Being Developed As A Therapy For Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures, And Bipolar Mania. Additionally, It Has Two Discovery-Stage Nicotinic Acetylcholine Receptor (Nachr) Programs Stemming From Its Rap Technology Platform: One Being Developed For The Treatment Of Chronic Pain, And The Second, Being Developed For The Treatment Of Hearing Disorders. Geographically, The Company Operates In The United States.